Skip to main content
OpenTrials

Clinical trial condition

Stage IV Bladder Cancer AJCC v8

Explore clinical trials studying Stage IV Bladder Cancer AJCC v8. Study availability and eligibility vary by location and protocol.

21 public trials 6 recruiting studies
Refine in advanced search Browse all conditions

Stage IV Bladder Cancer AJCC v8 trial results

Recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

NCT03866382

Conditions
Adenocarcinoma, Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, +71 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 581 locations
View Trial Details
Recruiting

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

NCT05756569

Conditions
Bladder Adenocarcinoma, Bladder Squamous Cell Carcinoma, Female Urogenital Diseases, +22 more
Locations
  • Grady Health System Atlanta, Georgia, United States
  • Emory University Hospital Midtown Atlanta, Georgia, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Emory Saint Joseph's Hospital Atlanta, Georgia, United States
View Trial Details
Active, not recruiting

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

NCT04579224

Conditions
Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +17 more
Locations
  • Kingman Regional Medical Center Kingman, Arizona, United States
  • Cancer Center at Saint Joseph's Phoenix, Arizona, United States
  • Mercy Hospital Fort Smith Fort Smith, Arkansas, United States
  • CHI Saint Vincent Cancer Center Hot Springs Hot Springs, Arkansas, United States
View all 448 locations
View Trial Details
Active, not recruiting

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

NCT03854474

Conditions
Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +16 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Smilow Cancer Hospital-Derby Care Center Derby, Connecticut, United States
  • Smilow Cancer Hospital Care Center-Fairfield Fairfield, Connecticut, United States
View all 34 locations
View Trial Details
Active, not recruiting

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

NCT04963153

Conditions
Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +36 more
Locations
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View Trial Details

Related conditions